Amneal Pharmaceuticals (AMRX) Proxy filing summary

Executive summary

• Announced acquisition of Kashiv BioSciences to create a fully integrated global biosimilars leader, aiming to become the top affordable medicines provider in the US.

• Transaction structured with $750M upfront (50% cash, 50% equity), up to $350M in milestones, and potential royalties over 12 years.

• Combined company expects to access over $300B in global biologic loss of exclusivity opportunities over the next decade.

• Q1 2026 showed strong financials: revenue up 4%, adjusted EBITDA up 19%, EPS up 29%, and net leverage reduced to 3.5x.

• Guidance raised for 2026; by 2030, revenues projected to grow 40% over 2026, with EPS up 70%.

Voting matters and shareholder proposals

• Shareholder approval is required for the acquisition of Kashiv BioSciences.

• Proxy materials will be filed and distributed to shareholders for voting on the proposed transaction.

Board of directors and corporate governance

• Proxy statement will include information on directors, executive officers, and their security holdings.

• Amneal Group, including both CEOs, are significant shareholders in both Amneal and Kashiv.